



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia
www.neuroscientific.com

Research and Development Program Update, 2 December 2019

Completion of dosing stage in Glaucoma study “Protective effects of intravitreal EmtinB in a pig model of raised IOP”

The Company is pleased to report that it has successfully completed the dosing stage of the Intraocular Pressure Glaucoma model (“IOP model”) in pigs, with ten animals successfully going through the treatment procedure. While its too early to judge on the success of the study, as this still requires analysis of a large amount of histological samples and neuronal markers, the company is pleased to report that execution of the experimental stage by the research team at the Lions Eye Institute was at the highest level and far exceeded our expectations. We are eagerly waiting for the data from this pivotal pre-clinical study in our ophthalmology program and expecting to report the results by the end of this month.

Success in this study would be a major outcome in ophthalmology and would present a major commercial opportunity in the Glaucoma field. Positive results will allow the Company to progress into testing of EmtinB in human Glaucoma patients next year and provide first evidence of the potential efficacy of EmtinB in patients with the Glaucoma, the leading cause of irreversible blindness in the world.

CVN Alzheimer’s mouse model study results to be released shortly

The Company is pleased to report that the final data from CVN mouse model is expected this week with the statistical analysis of the data to take place within the 48 hours following receipt of the data. Technical issues with the fluorescence scanning equipment had caused the slight delay in finalizing the CVN mouse study. Other than that, the experimental work was conducted as per the original protocol with no safety and toxicology events. The most valuable end points of the study will be changes in biochemical and immunological markers, as well as cognitive end points.

End

About NeuroScientific Biopharmaceuticals Ltd

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company’s product portfolio includes EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Mr Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Chairman
bl@@neuroscientific.com
+61 (0) 412 281 780